Cholesterol management is an important part of preventing and treating heart disease, stroke, and blood vessel blockages. Excess “bad cholesterol,” known as LDL cholesterol, can gradually build up inside the arteries and form plaques, leading to narrowing of blood vessels and reduced blood flow to the heart and other organs. Over time, this can result in heart attack, stroke, peripheral artery disease, or worsening cardiovascular health if not properly controlled.
High cholesterol often develops silently without causing symptoms, which is why regular screening is important, especially in individuals with diabetes, high blood pressure, obesity, smoking history, family history of heart disease, or previous cardiac events. Blood tests help measure cholesterol levels and assess cardiovascular risk. Early detection and proper treatment can significantly reduce future heart-related complications.
Lifestyle modification plays a major role in cholesterol management. Patients are advised healthy diet, reduced intake of saturated fats and processed foods, regular exercise, weight control, smoking cessation, stress reduction, and diabetes management. However, many patients also require medications to achieve adequate cholesterol reduction and protect the heart.
Statins are the most commonly used cholesterol-lowering medications and remain the foundation of treatment for many patients. These medicines help reduce LDL cholesterol levels, stabilize plaque inside arteries, and lower the risk of heart attack and stroke. Additional oral medications such as ezetimibe may also be added in selected patients when cholesterol remains elevated despite treatment.
Modern cholesterol management now includes advanced injectable therapies for patients with very high cholesterol levels, genetic cholesterol disorders, recurrent cardiovascular disease, or inadequate response to oral medications alone. PCSK9 inhibitors are a newer group of injectable medications that significantly lower LDL cholesterol levels by improving the body’s ability to remove cholesterol from the bloodstream. These injections are usually given once every two to four weeks and can produce substantial cholesterol reduction.
Inclisiran is another advanced injectable cholesterol-lowering therapy that works by reducing the production of PCSK9 protein in the liver. One of its major advantages is that it requires infrequent dosing, usually once every six months after the initial doses. This can improve treatment convenience and long-term cholesterol control in selected patients.
These advanced injectable therapies are particularly useful in high-risk patients such as those with previous heart attacks, severe coronary artery disease, familial hypercholesterolemia (genetic high cholesterol), stroke, or patients unable to achieve target cholesterol levels despite multiple oral medications. Treatment decisions are individualized based on overall cardiovascular risk and cholesterol profile.
Modern cholesterol management focuses not only on reducing cholesterol numbers but also on preventing future heart attacks, strokes, and progression of cardiovascular disease. With proper lifestyle changes, regular follow-up, and advanced treatment options including both oral and injectable therapies, long-term heart and vascular health can be significantly improved.
ESC
